The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
Acta Microbiologica et Immunologica Hungarica · 05.03.2026 · 73 (1) · 13-19
DOI: 10.1556/030.2025.02719 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, erschienen am 05.03.2026. Verfasst von Zheying Ni und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Gastroenterology, Hangzhou Fuyang Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, 311400, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
The gut microbiota has emerged as a critical determinant of antitumor immunity and a potential modulator of responses to immune checkpoint inhibitors (ICIs). Although pre-clinical and clinical studies suggest that specific bacterial taxa may influence both efficacy and immune-related adverse events (irAEs). However, the magnitude and consistency of these associations remain unclear. A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted through March 2025. Eligible studies evaluated baseline gut microbiota composition, fecal microbiota transplantation (FMT), probiotic/prebiotic interventions, or antibiotic exposure in cancer patients treated with ICIs. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for response rates and irAEs, were estimated using random-effects models. Across 38 studies involving 5,642 patients were included. Pooled analysis demonstrated that enrichment of Akkermansia muciniphila , Bifidobacterium longum and Faecalibacterium prausnitzii was significantly associated with improved OS (HR 0.62, 95% CI 0.51–0.76) and PFS (HR 0.69, 95% CI 0.55–0.83). Conversely, antibiotic exposure before or during ICI treatment was associated with worse OS (HR 1.84, 95% CI 1.45–2.34). Patients undergoing FMT from responders exhibited higher objective response rates (OR 2.91, 95% CI 1.48–5.73). Microbiota diversity indices were consistently higher in responders than in non-responders. Collectively, gut microbiota composition and its modulation significantly impact the therapeutic efficacy and toxicity profile of ICIs. These findings highlight the translational potential of microbiome-based biomarkers and interventions in optimizing immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Gastroenterology, Hangzhou Fuyang Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, 311400, China.
- 2Department of Oncology, Chun'an First People's Hospital, Hangzhou, No.1869, Huanhu North Road, Qiandao Lake Town, Chun'an County, Zhejiang Province, 311700, China.
ORCID-Profile: Dan Ye
Zitieren
APA
Ni, Z., & Ye, D. (2026). The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer. Acta Microbiologica et Immunologica Hungarica, 73(1), 13-19. https://doi.org/10.1556/030.2025.02719
Vancouver
Ni Z, Ye D. The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer. Acta Microbiologica et Immunologica Hungarica. 2026;73(1):13-19. doi:10.1556/030.2025.02719
BibTeX
@article{Ni2026,
author = {Ni, Zheying and Ye, Dan},
title = {The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2026},
volume = {73},
number = {1},
pages = {13--19},
doi = {10.1556/030.2025.02719}
}
EUVIMED